Attovia Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATTO research report →
Range $39 – $52
Price Chart
About the company
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
- CEO
- Tao Fu
- IPO
- 2026
- Employees
- 44
- HQ
- San Carlos, CA, US
AI snapshot
Six angles, distilled from the data.
ATTO is still in a post-IPO downtrend, trading below its 200-day average of 18.56 and 50-day average of 17.53. The stock sits well under its 52-week high of 28, but it has rebounded from the 12.94 low, suggesting an early recovery attempt rather than a confirmed trend reversal.
Street sentiment is constructive, with a Buy consensus and a 45.33 average target versus a 15.13 last close. Recent initiations were uniformly positive: RBC at Outperform, Morgan Stanley at Overweight, Citigroup at Buy, and Leerink at Outperform with a 52 target, signaling broad early coverage support.
The earnings profile is still loss-making, and the company has missed both reported quarters, including a -2.7% EPS miss in the latest print. Estimates point to a smaller loss next year, with 2026 EPS at -4.19 and 2027 improving to -2.47, so shareholders should watch burn rate and clinical progress more than near-term profitability.
The pattern is net buying, but most of the large share counts are award or conversion activity rather than open-market conviction. The clearest discretionary signal is director Colin Walsh’s 500,000-share purchase on August 6, alongside a smaller 5,744-share buy, while CEO and CFO awards add size but are not the same as cash buying.
ATTO remains deeply unprofitable, with a -48.45% operating margin and negative free cash flow of $56.9 million in fiscal 2025. The balance sheet is the offset: $152.3 million of cash against $5.26 million of debt leaves $147.0 million in net cash, giving the company runway while development spending stays high.
As a clinical-stage biotech, ATTO trades on pipeline optionality rather than current earnings power, so it screens more like a funded development story than a mature peer. The setup favors a premium multiple only if clinical execution improves; otherwise the valuation remains highly sensitive to trial milestones and cash burn.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $690.26M
- P/E
- -8.26
- PEG
- 0.23
- P/S
- 471.73
- P/B
- 10.97
- EV/EBITDA
- -6.71
- Div Yield
- 0.00%
- Gross Margin
- 32.85%
- Op Margin
- -5945.49%
- Net Margin
- -5477.22%
- ROE
- -58.88%
- ROIC
- -21.28%
Latest fiscal year · YoY change
- Revenue
- $1.35M+0.0%
- Gross Profit
- $546.00K+274.4%
- Op Income
- $-67,159,000
- Net Income
- $-60,627,000-52.3%
- EPS
- $-1.42-35.2%
- OCF Growth
- -69.0%
- FCF Growth
- -67.1%
- 52W High
- $28.00
- 52W Low
- $12.94
- 50D MA
- $16.85
- 200D MA
- $18.38
- Beta
- 0.00
- RSI (14)
- 49
- Avg Volume
- 337.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Atento said Q3 showed the payoff from its restructuring, with EBITDA margin improving sharply and management sounding more confident on Q4 cash generation and 2023 growth, despite softer volumes in Brazil and high financial expenses.· November 16, 2022
- EBITDA margin improved sequentially to 11.1% from 7.8% in Q2, and management said Q4 margin should be 14% to 15%.
- Revenue rose 1.1% sequentially on a constant-currency basis; versus Q3 2021, constant-currency revenue was down 0.4%.
- Management said sales grew 10.3% year over year and that Q4 sales should support a stronger start to 2023.
- Cash was pressured by $46 million of finance expense in the quarter; cash fell from $103 million at Q2 to $66 million at Q3, with Q4 expected to rebuild cash to about $90 million to $100 million.
- Atento launched operations in the Philippines, with first-year revenue expected at $20 million to $50 million, and said the initiative is intended to be self-funding and positive within the year.
Atento did not disclose full company revenue or EPS in the prepared remarks, but management said constant-currency revenue increased 1.1% sequentially in Q3 and was down 0.4% year over year. EBITDA margin was 11.1% in Q3, up 3.3 percentage points sequentially from 7.8% in Q2, and down 2.3 percentage points year over year; Brazil EBITDA margin was 10.8%. Operating cash flow was positive $8 million, cash EBITDA/U.S. GAAP EBITDA was $25 million after leases, working capital was a negative $5 million, finance expense was $46 million, and cash ended at $66 million versus $103 million at Q2. Management guided to Q4 EBITDA margin of 14% to 15% and full-year EBITDA margin of 10.5% to 11%; they also said Q4 free cash flow should be around $40 million and cash should finish the year in the $90 million to $100 million range.
Carlos López-Abadía framed 2022 as more difficult than expected but said the first-half actions are starting to show results. He emphasized five priorities: expanding sales, accelerating operational efficiencies, improving cost structure, managing inflation pass-through, and strengthening security, and said these are helping the company exit 2022 on a stronger footing. His tone was constructive and pragmatic: he acknowledged weak demand in some customers, especially in Brazil, but repeatedly argued that the changes are structural rather than just cost cuts and should support a stronger 2023.
Sergio Passos focused on the sequential improvement in KPIs and the cash bridge. He highlighted the move in EBITDA margin from 7.8% to 11.1%, the positive 1.1% sequential revenue change, the $25 million cash EBITDA/U.S. GAAP EBITDA after leases, and the $8 million operating cash flow, while explaining that Q3 free cash flow was hit by the timing of $46 million in finance expense, including bond and hedge payments. He said cash was $66 million at quarter-end, expected to recover to $90 million to $100 million in Q4, and noted net leverage of 6.1x EBITDA, with all facilities renewed and the $43 million IDB super-senior facility remaining available under covenant compliance.
Analysts focused on the lower guidance, asking whether visibility was good enough to support the revised full-year outlook and what Q4 margin implied. Management said they are roughly halfway through Q4, have good visibility, and expect Q4 EBITDA margin to be in the 14% to 15% range, which should support the full-year target and a Q4 cash rebound. Another area of focus was liability management and liquidity; management said it is reviewing proposals from existing investors and international banks, including receivables-backed options, and that 2023 should be the last year of abnormally high financial expenses. Questions also covered the Philippines expansion, where management said the launch is self-funding, based on committed customer demand, and strategically useful for U.S. nearshore/offshore coverage.
The call suggested that Atento’s restructuring is beginning to translate into better margins, with Q3 EBITDA margin up 3.3 points sequentially and Q4 expected to improve further. Management also pointed to improved sales momentum, a stronger pipeline, and the Philippines launch as additional growth levers, while saying cash should rebound materially in Q4 and financial expenses should ease after 2023.
The main risks discussed were customer volume softness, especially in Brazil, price pressure in legacy contracts, and continued uncertainty in the macro environment. Management also acknowledged high financing costs, a cash drop to $66 million, leverage at 6.1x EBITDA, and negative equity of $165 million, all of which keep the balance sheet a visible concern even as operations improve.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 62.3%
- Shares Outstanding
- 45.71M
- Float Shares
- 28.48M
of shares held by institutions
1 13F filers
Buy/sell ratio 2.83. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Balter Liquid Alternatives, LLC | 361.67K | ▲ 89.27K |
| Jump Trading, LLC | 18.26K | ▲ 18.26K |
Held by 32 ETFs
Biggest fund positions in ATTO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 26 | Fu Tao | other | 538,300 |
| Aug 4, 26 | Chan Steven | other | 140,000 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Fu Tao | other | 0 |
| Aug 4, 26 | Chan Steven | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATTO coverage
Recent articles, reports, and earnings notes.

Attovia's $20.6 million insider bet changes the IPO story
Attovia's insider signal is bullish, but the cleanly supported figure is $10.29 million rather than the touted $20.57 million. The smaller number still matters because it arrived alongside a roughly $289 million IPO and a lead asset already tested in humans.

Attovia Therapeutics IPO: What Investors Need to Know
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.

Atento S.A. IPO: What Investors Need to Know
Atento S.A. is expected to list on NASDAQ on 2026-08-05 in a 12,500,000-share offering priced at $15.00 to $17.00 per share. The implied market cap is $244,375,000 if priced at the midpoint. The bull case is a scaled CRM/BPO platform with AI and nearshore delivery; the bear case is that the company already appears to be a long-established public issuer, so investors should watch closely for confirmation of what is actually being offered.
Want a deeper read on ATTO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript
seekingalpha.com · Nov 9
Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com · Nov 9
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials
marketbeat.com · Nov 6
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
globenewswire.com · Nov 5
Attovia Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 27
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
globenewswire.com · Sep 28
Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Attovia Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice